Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
US-2018055926-A1 · Mar 1, 2018 · US
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
US12377068B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12377068-B2 |
| Application number | US-202418642051-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 22, 2024 |
| Priority date | May 16, 2018 |
| Publication date | Aug 5, 2025 |
| Grant date | Aug 5, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating a pediatric cancerous solid tumor selected from one or more of the group consisting of Ewing sarcoma, neuroblastoma, osteosarcoma, neuroepithelioma, and rhabdomyosarcoma in a mammalian subject that comprises (1) intralesionally administering an amount of rose bengal or a pharmaceutically acceptable salt thereof that elicits ablation of tumor cells and (2) administering a tumor-inhibiting effective amount of one or more checkpoint inhibitor antibodies that binds with the PD-1 receptor, the PD-L1 receptor, or the CTLA-4 receptor. 2. The method according to claim 1 , wherein said rose bengal is rose bengal disodium. 3. The method according to claim 1 , wherein said intralesional administration of rose bengal or a pharmaceutically acceptable salt thereof occurs prior to administration of said one or more checkpoint inhibitor antibodies. 4. The method according to claim 1 , wherein said intralesional administration of rose bengal or a pharmaceutically acceptable salt thereof occurs after administration of said one or more checkpoint inhibitor antibodies. 5. The method according to claim 1 , wherein said intralesional administration of rose bengal or a pharmaceutically acceptable salt thereof occurs concurrent with administration of said one or more checkpoint inhibitor antibodies. 6. The method according to claim 1 , wherein said mammal is a human.
Assignees
Inventors
Classifications
- A61K31/352Primary
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
against CD28 or CD152 · CPC title
against B7 molecules, e.g. CD80, CD86 · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Heavy metals; Compounds thereof · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12377068B2 cover?
- A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering …
- Who is the assignee on this patent?
- Provectus Pharmatech Inc, Uti Lp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/352. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).